American Society of Dentist Anesthesiologists

Novel Medications for Dental Anesthesia Practice in the Year 2020 - ASDA

Novel Medications for Dental Anesthesia Practice in the Year 2020

Sean Thoms, DMD, MS, DADBA

This session was recorded via live Broadcast on November 21, 2020. It is available for On-Demand CE.

This Broadcast is eligible for 1 unit On-Demand CE, provided a 70% or higher is obtained on the post session quiz.


Not an ASDA member? Members qualify for preferential pricing. Learn more.



This presentation will introduce new medications, discuss their pharmacologic properties, and dive into clinical applications useful for the Dentist Anesthesiologist.

Attendees will come away with an introduction to the following novel medications:

  1. BYFAVO® (Remimzolam): a new sedative with an ultra-short half-life that will improve safety of moderate sedation in dentistry.
  2. CLEVIPREX® (Clevidipine): A fast-acting, ultra-short half-life dihydropyridine calcium channel blocker used to rapidly reduce systolic blood pressure within two minutes of initial dosing.
  3. DSUVIA® (Sublingual Sufenanil): an enteral form of sufentanil FDA approved for management of moderate to severe pain.
  4. EXPAREL® (Liposomal Bupivicaine): Bupivicaine encapsulated in multivesicular liposomes injected locally for long lasting post-surgical pain management.
  5. AKYNZEO® (Netupitant/Palonosetron): An anti-nausea medication for treatment of chemotherapy induced nausea and vomiting utilizing both a NK-1 receptor antagonist and a 5-HT3 receptor antagonist in one pill or injectable.



WordPress Lightbox